Opportunities and challenges in the nanoparticles for nucleic acid therapeutics: the first approval of an RNAi nanoparticle for treatment of a rare disease

作     者：Xiawei Wei Yuquan Wei 

作者机构：Laboratory of Aging Research and NanotoxicologyState Key Laboratory of Biotherapy National Clinical Research Center for Geriatrics West China Hospital Sichuan University 

出 版 物：《National Science Review》 (国家科学评论(英文版))

年 卷 期：2019年第6卷第6期

页      面：1105-1106页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 07[理学] 070205[理学-凝聚态物理] 08[工学] 1010[医学-医学技术（可授医学、理学学位）] 080501[工学-材料物理与化学] 0805[工学-材料科学与工程（可授工学、理学学位）] 100215[医学-康复医学与理疗学] 10[医学] 0702[理学-物理学] 

基　　金：supported by the National Key Research and Development Program of China(2016YFA0201402) the National Major Scientific and Technological Special Project for ‘Significant New Drugs Development’(2018ZX09733001) the National Natural Science Foundation of China(81602492) 

主　　题：the first approval of an RNAi nanoparticle for treatment of a rare disease Opportunities and challenges in the nanoparticles for nucleic acid therapeutics 

摘      要：Nanoparticle-based nucleic acid therapeutics have drawn considerable attention over recent decades. By using terms such as ‘nanoparticle’ and ‘gene delivery’ in a Pub Med search, we found that 10 years ago throughout 2008 there were only 725 such papers published;however, in 2017, over 4700 papers were published with the same keywords.